Inex Pharmaceuticals Announces Appeal Date for Spin-out of Tekmira Pharmaceuticals

18-Jan-2007

Inex Pharmaceuticals Corporation announced that on February 6, 2007 the British Columbia Court of Appeal will hear Protiva Biotherapeutics, Inc. ("Protiva") appeal of the Supreme Court of British Columbia's ruling that approved the INEX Plan of Arrangement to transfer all of the Company's transferable assets and liabilities to a spin-out Company, Tekmira Pharmaceuticals Corporation ("Tekmira"). The Supreme Court of British Columbia approved the Plan of Arrangement on November 24, 2006.

INEX believes the original decision of the Supreme Court of British Columbia was correct and the Company will continue to defend its position. The completion of the Tekmira spin-out is now expected to be completed by the end of February 2007.

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Dharmacon's completion of first human genome-wide siRNA library signals new era in life-science research

Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

LFE Laboratorium für industrielle Forschung GmbH & Co. Entwicklungs KG - Bruchköbel, Germany

Andromeda Biotech Successfully Completes Patient Recruitment in Phase III Trials for DiaPep277 for Type 1 Diabetes

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Stora Enso and Gasum to make renewable energy from wastewater in Sweden

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Antibiotic-Resistant Bacteria Have Evolved a Unique Chemical Mechanism, New Discovery Reveals